Cargando…

Activating HER3 mutations in breast cancer

Recent studies have highlighted a role of HER3 in ER and HER2-driven breast cancers. We sought to investigate the role of patient-derived HER3 mutations in ER+ and HER2+ breast cancer cells using ectopic expression of HER3 mutants. We found that HER3(T355I) mutant is activating with increased cell p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Rosalin, Alanazi, Samar, Yuan, Long, Solomon, Thomas, Thaker, Tarjani M., Jura, Natalia, Garrett, Joan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021238/ https://www.ncbi.nlm.nih.gov/pubmed/29963236 http://dx.doi.org/10.18632/oncotarget.25576

Ejemplares similares

HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
por: Alanazi, Samar M., et al.
Publicado: (2023)

HER3 Alterations in Cancer and Potential Clinical Implications
por: Kilroy, Mary Kate, et al.
Publicado: (2022)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
por: Mishra, Rosalin, et al.
Publicado: (2021)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
por: Yuan, Long, et al.
Publicado: (2020)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)

Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma
por: Yuan, Long, et al.
Publicado: (2018)

Genomic alterations of ERBB receptors in cancer: clinical implications
por: Mishra, Rosalin, et al.
Publicado: (2017)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
por: Frazier, Nicole Michael, et al.
Publicado: (2018)

Functional role of PGAM5 multimeric assemblies and their polymerization into filaments
por: Ruiz, Karen, et al.
Publicado: (2019)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2018)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer
por: Zhang, Shu, et al.
Publicado: (2016)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer
por: Wymant, Jennifer Mary, et al.
Publicado: (2020)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015)

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2015)

Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice
por: Dupouy, Sandra, et al.
Publicado: (2014)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

HER3 and LINC00052 interplay promotes tumor growth in breast cancer
por: Salameh, Ahmad, et al.
Publicado: (2016)

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis
por: Wang, Ju, et al.
Publicado: (2020)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2015)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t0csl6ph2gnoof7073ap964h0f